Boubaker 2012.

Clinical features and settings	Inclusion period: n.r. Patient population: 357 patients with newly diagnosed high risk stage 4 neuroblastoma (HR‐NBL1/SIOPEN trial). Consecutive series: n.r. Diagnostic work‐up: n.r. Time spans symptoms‐index test, symptoms‐reference standard and index test‐reference standard: n.r. Treatment between index test‐reference standard: n.r.
Participants	Included patients: 357 patients with newly diagnosed high risk stage 4 neuroblastoma. Median age at first diagnosis: n.r. Sex distribution: n.r. INSS stage: n.r.
Study design	Cohort study with patients from the (HR‐NBL1/SIOPEN trial). N.r. whether the study was retrospective or prospective.
Target condition and reference standard(s)	Target condition: newly diagnosed high risk stage 4 neuroblastoma. Reference standard: n.r.
Index and comparator tests	Index test: ¹²³I‐MIBG scintigraphy. Radiofarmacon: ¹²³I‐MIBG. Dose: n.r. Collimator: n.r. Matrix: n.r. Acquisition protocol: n.r. Acquisition time: n.r. Acquisition duration: n.r. Interfering medication: not reported. Thyroid prophylaxis: not reported. Positive test result: skeletal ¹²³I‐MIBG uptake. Number and expertise of observers: eight nuclear medicine experts in four groups. Interobserver concordance: n.r.
Follow‐up	n.r.; some patients were followed for approximately five years.
Notes	This study has not been published in full‐text (as of December 2012), but has been presented at the ANR conference 2012. Results not reported for ¹²³I‐MIBG scans at first diagnosis separately from the ¹²³I‐MIBG scans during follow‐up. We could not get in contact with the study authors.